The peptide treatments remarkably suppressed the expressions of a few enzymes appeared to be more active in cancers, for example, triosephosphate isomerase (TPI), argininosuccinate synthase 1 (ASS1), carbamoyl-phosphate synthase 1 (CPS1), aldo-keto reductase family 1 member B10 (AKR1B10), lactate dehydrogenase B (LDHB) and phosphoglycerate kinase 1 (PGK1). The gene discussed is AKR1B10; the disease is cancer.